Literature DB >> 15168797

Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus.

Kazufumi Kimura1, Ken Ishioka, Koichi Hashimoto, Schuichi Mori, Tatsuo Suzutani, Terry L Bowlin, Shiro Shigeta.   

Abstract

We obtained two mutant strains of respiratory syncytial virus (RSV) which showed resistance against NMSO3 after 15 and 33 passages, respectively, in HEp-2 cells in the presence of 6.8 microM of NMSO3. The EC50 values of NMSO3 for the resistant virus strains were 0.48 and 0.93 microM, that is 4.8-9.3 times higher than that of the parent strain (EC50 = 0.1 microM). The most resistant strain also showed resistance against heparin but was sensitive to dextran sulfate and a polyoxotungstate, PM-523. In order to determine whether the acquisition of resistance to NMSO3 was the result of the accumulation of genetic changes of virus, we sequenced the G- and F-protein genes. In comparison with the standard type of RSV strains, we identified changes of 10 amino acids in the G protein including those at the central conserved segment. However, we did not observe any particular changes in the amino acid sequence of the F-protein of the resistant strains. From these results, we conclude that NMSO3 inhibits the G-protein interaction to the receptor. The mutations in the G-protein may result in the observed phenotypic resistance of RSV towards NMSO3.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168797     DOI: 10.1016/j.antiviral.2003.09.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 2.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

Review 3.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

4.  Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.

Authors:  Valeria Cagno; Manuela Donalisio; Andrea Civra; Marco Volante; Elena Veccelli; Pasqua Oreste; Marco Rusnati; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

5.  Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide.

Authors:  Manuela Donalisio; Marco Rusnati; Valeria Cagno; Andrea Civra; Antonella Bugatti; Andrea Giuliani; Giovanna Pirri; Marco Volante; Mauro Papotti; Santo Landolfo; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

6.  Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection.

Authors:  Zhiwu Sun; Qian Wang; Ran Jia; Shuai Xia; Yuan Li; Qi Liu; Wei Xu; Jin Xu; Lanying Du; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2015-02-16       Impact factor: 5.048

Review 7.  Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.

Authors:  Jennifer A Pickens; Ralph A Tripp
Journal:  Viruses       Date:  2018-01-21       Impact factor: 5.048

8.  A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus.

Authors:  Dong-Hoon Chung; Blake P Moore; Daljit S Matharu; Jennifer E Golden; Clinton Maddox; Lynn Rasmussen; Melinda I Sosa; Subramaniam Ananthan; E Lucile White; Fuli Jia; Colleen B Jonsson; William E Severson
Journal:  Virol J       Date:  2013-01-10       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.